Citius Oncology (CTOR) Restructuring Costs (2022 - 2026)

Citius Oncology (CTOR) has reported Restructuring Costs for 5 consecutive years, with $999319.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Restructuring Costs rose 75.96% year-over-year to $999319.0 in Q2 2026; TTM through Jun 2026 was $2.6 million, a 15.52% decrease from a year earlier, with the FY2025 full-year figure at $2.2 million, up 19.26% from the prior year.
• Restructuring Costs was $999319.0 for Q2 2026 at Citius Oncology, up from $567937.0 in the prior quarter.
• Over five years, Restructuring Costs peaked at $1.3 million in Q2 2024 and troughed at $21666.0 in Q4 2022.
• A 5-year average of $503351.6 and a median of $532937.0 in 2024 frame the typical range for Restructuring Costs.
• Across the five-year window, Restructuring Costs jumped 4334.55% in 2024 and plunged 57.31% in 2025, its largest moves.
• Over 5 years, Restructuring Costs stood at $21666.0 in 2022, then surged by 1849.05% to $422282.0 in 2023, then jumped by 34.49% to $567937.0 in 2024, then slipped by 12.33% to $497937.0 in 2025, then jumped by 100.69% to $999319.0 in 2026.
• The last three Restructuring Costs figures came in at $999319.0 (Q2 2026), $567937.0 (Q1 2026), and $497937.0 (Q4 2025), per Business Quant data.